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Mutations in GJB2, the gene encoding connexin-26 at the DFNB1 locus on 13q12, are found in as many as 50% of
subjects with autosomal recessive, nonsyndromic prelingual hearing impairment. However, genetic diagnosis is com-
plicated by the fact that 10%–50% of affected subjects with GJB2 mutations carry only one mutant allele. Recently,
a deletion truncating the GJB6 gene (encoding connexin-30), near GJB2 on 13q12, was shown to be the accompanying
mutation in ∼50% of these deaf GJB2 heterozygotes in a cohort of Spanish patients, thus becoming second only to
35delG at GJB2 as the most frequent mutation causing prelingual hearing impairment in Spain. Here, we present
data from a multicenter study in nine countries that shows that the deletion is present in most of the screened
populations, with higher frequencies in France, Spain, and Israel, where the percentages of unexplained GJB2 het-
erozygotes fell to 16.0%–20.9% after screening for the del(GJB6-D13S1830) mutation. Our results also suggest that
additional mutations remain to be identified, either in DFNB1 or in other unlinked genes involved in epistatic inter-
actions with GJB2. Analysis of haplotypes associated with the deletion revealed a founder effect in Ashkenazi Jews
and also suggested a common founder for countries in Western Europe. These results have important implications
for the diagnosis and counseling of families with DFNB1 deafness.
Hearing impairment is the most common sensory dis-
order. In developed countries, 160% of the cases are
due to genetic causes (Petit et al. 2001). Nonsyndromic
forms, in which the hearing deficit is the only clinical
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sign, are highly heterogeneous, with 180 loci already
reported and 30 genes identified so far (Hereditary Hear-
ing Loss Homepage). Hearing impairment that manifests
before speech acquisition (i.e., with prelingual onset) is
mainly inherited in an autosomal recessive pattern, with
31 different loci and 16 currently identified genes (He-
reditary Hearing Loss Homepage).
The DFNB1 locus for nonsyndromic, autosomal re-
cessive, prelingual hearing impairment (MIM 220290)
was mapped to the 13q12 region (Guilford et al. 1994).
This locus contains the GJB2 gene (MIM 121011), en-
coding connexin-26 (Cx26), a transmembrane protein
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subunit of intercellular gap junctions (Kelsell et al. 1997).
Six monomers of connexin bind together to form a hex-
amer (connexon), which, in turn, docks with another con-
nexon on the surface of an adjacent cell to form an in-
tercellular gap-junction channel (Goodenough et al. 1996;
Kumar and Gilula 1996). In the cochlea, there are two
networks of gap junctions, the epithelial cell system and
the connective tissue cell system, which are thought to be
involved in the recycling of potassium back into the coch-
lear endolymph, where it plays an essential role in sound
transduction (Kikuchi et al. 2000). In fact, targeted in-
activation of the GJB2 gene in the inner-ear epithelial
network led to hearing impairment in mice, demonstrat-
ing the key role of this network in cochlear function and
cell survival (Cohen-Salmon et al. 2002). Several different
connexins have been shown to participate in these gap
junction systems. To date, mutations in the genes encoding
three of these connexins (GJB2 for Cx26, GJB6 for Cx30
[MIM 604418], and GJB3 for Cx31 [MIM 603324]) are
known to result in hearing impairment (Kelsell et al. 1997;
Xia et al. 1998; Grifa et al. 1999). Among them, GJB2
stands out, because mutations in this gene account for as
many as 50% of all cases of prelingual hearing impair-
ment in many populations (Rabionet et al. 2000). More
than 80 different mutations in GJB2 have been described
in subjects with hearing impairment (Connexin-Deafness
Homepage). Molecular testing for GJB2 mutations has
rapidly become the standard of care for the diagnosis and
counseling of patients with nonsyndromic hearing im-
pairment of unknown cause.
Mutation screening of GJB2 in subjects with autosomal
recessive hearing impairment has, however, revealed an
unexpected problem—namely, a high number of patients
carrying only one mutant allele. Exhaustive screening of
the coding region (fully contained in exon 2), exon 1, and
splice sites did not reveal any mutation in the second allele.
These cases accounted for 10%–50% of all deaf subjects
with at least one GJB2 mutation. These findings could
be attributed to intrinsic limitations in the techniques used
for mutation screening, to the high frequency of carriers
for some GJB2 mutations, or to the existence of mutations
in other noncoding parts of the gene that have not yet
been identified. However, it was also suspected that other
mutations might exist, in the DFNB1 locus but not in the
GJB2 gene, that could provide an explanation for the high
proportion of heterozygous affected subjects. Recently,
this hypothesis received experimental support from the
finding of a novel class of mutations in the DFNB1 locus,
which were deletions not affecting GJB2 but truncating
the neighboring GJB6 gene, which encodes Cx30. These
deletions were found accompanying in trans the only
GJB2 mutant allele in heterozygous affected subjects
(double heterozygosity) (Lerer et al. 2001; del Castillo et
al. 2002; Pallares-Ruiz et al. 2002) and were also found
to be the cause of deafness in three unrelated affected
subjects who were homozygous for the deletion (del Cas-
tillo et al. 2002; Pallares-Ruiz et al. 2002). In one study,
the deletion breakpoint junction was isolated and se-
quenced, revealing the loss of a DNA segment of ∼342
kb, with one breakpoint inside the GJB6 coding region
(del Castillo et al. 2002). This deletion, named “del(GJB6-
D13S1830),” was the accompanying mutation in ∼50%
of the deaf GJB2 heterozygotes (del Castillo et al. 2002).
It remained to be determined whether the deletions de-
tected by other groups (Lerer et al. 2001; Pallares-Ruiz
et al. 2002) were also del(GJB6-D13S1830).
These findings may indicate a digenic pattern of in-
heritance of hearing impairment from mutations involv-
ing GJB2 and GJB6. This hypothesis is supported by
several facts: (i) both Cx26 and Cx30 are expressed in
the same inner-ear structures (Lautermann et al. 1998,
1999), (ii) connexons composed of Cx26 can bind con-
nexons composed of Cx30 to form heterotypic gap-junc-
tion channels (Dahl et al. 1996), (iii) a mutation in GJB6
was reported in a case of autosomal dominant hearing
impairment (Grifa et al. 1999), and (iv) Cx30-deficient
mice exhibit a severe constitutive hearing impairment
and lack an endocochlear potential (Teubner et al.
2003). However, the fact that point mutations in GJB6
have not yet been found in cases of autosomal recessive
hearing impairment argues against this hypothesis. An
alternative explanation is that the deletion may eliminate
an upstream regulatory element for GJB2 that is essen-
tial for the normal expression of this gene in the inner
ear. So far, such an element has not been found.
Given the association previously found between GJB2
monoallelic mutations and the del(GJB6-D13S1830)
mutation in several studies (Lerer et al. 2001; del Castillo
et al. 2002; Pallares-Ruiz et al. 2002), we investigated
the contribution of this deletion to hearing impairment
in nine countries. A genetic analysis of five microsatellite
markers flanking the deletion breakpoints was also con-
ducted, to determine the haplotypes associated with the
del(GJB6-D13S1830) mutation and to explore its evo-
lutionary origins. The implications of our results for mo-
lecular diagnosis of DFNB1 mutations are presented.
The study was performed on probands with nonsyn-
dromic prelingual hearing impairment from nine coun-
tries (table 1). In Spain, Israel, and the United States, two
independent studies were performed. After getting written
informed consent, blood samples were obtained, and
DNA was extracted by standard procedures. Testing for
the del(GJB6-D13S1830) mutation was performed using
the previously reported primers GJB6-1R (forward) and
BKR-1 (reverse) (del Castillo et al. 2002), as well as a
modification of the method to positively detect a wild-
type product by adding another reverse primer that is
located in the deleted segment of GJB6 (R2, 5′-TCATCG-
GGGGTGTCAACAAACA-3′). When these three primers
were used together, two different PCR products were ob-
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Table 1
Results from the Screenings for the del(GJB6-D13S1830) Mutation
Country/Laboratory
No. of (del[GJB6-D13S1830]GJB2)
Double Heterozygotes/
No. of GJB2 Heterozygotes
No. of del(GJB6-D13S1830)
Homozygotes/Total Screened
Spain/Madrida 29/68 (42.6%)b 1/425 (.2%)  2 heterozygotesc
Spain/Barcelona 5/35 (14.3%) 1/236 (.4%)
Italy 0/31 (.0%) 0/238 (.0%)  1 heterozygotec
France 23/60 (38.3%) 0/208 (.0%)  1 heterozygotec
Belgium 2/19 (10.5%) 0/151 (.0%)
United Kingdom 6/19 (31.6%) Not performed
Israel/Tel Aviv 7/20 (35.0%) 1/191 (.5%)
Israel/Jerusalem 5/7 (71.4%) Not performed
United States/Virginia 14/88 (15.9%) 1/486 (.2%)  4 heterozygotesc
United States/Iowa 7/95 (7.4%) Not performed
Brazil 2/9 (22.2%) Not performed
Australia 2/29 (6.9%) Not performed
a This work expands the results of a previous study (del Castillo et al. 2002).
b By performing haplotype analysis for genetic markers from 13q12, linkage to DFNB1 was
excluded in 11 cases. After correction, the figures are 29/57 (50.9%).
c Number of del(GJB6-D13S1830) heterozygotes with no mutation in GJB2.
tained—GJB6-1RrR2 (681 bp) and GJB6-1RrBKR-1
(460 bp)—allowing for discrimination between wild-type
subjects (681-bp product), homozygotes for the deletion
(460-bp product), and heterozygotes (both products) in
a single test. In all subjects carrying the deletion, the PCR
product that contains the breakpoint junction of the de-
letion was sequenced, to confirm that the breakpoint junc-
tion was identical in all cases. Thus, we confirmed that
all the deletions reported by Lerer et al. (2001) were
del(GJB6-D13S1830). In an independent study, it was
also shown that the deletions reported by Pallares-Ruiz
et al. (2002) were del(GJB6-D13S1830) (A. F. Roux, per-
sonal communication).
Two different screenings were performed, the first on
deaf subjects carrying only one GJB2 mutant allele,
which had been found during routine testing for GJB2
mutations (tables 1 and 2); and the second on subjects
with nonsyndromic prelingual hearing impairment, car-
rying no mutation in GJB2 (table 1). The frequency of
the del(GJB6-D13S1830) allele among DFNB1 alleles is
shown in table 3.
The del(GJB6-D13S1830) allele is most frequent in
Spain, France, the United Kingdom, Israel, and Brazil,
accounting for 5.9%–9.7% of all the DFNB1 alleles
(table 3). Its frequency is lower in Belgium and Australia
(1.3%–1.4%), and it has not been found among Italian
GJB2 unelucidated heterozygotes. In the United States,
two different screenings yielded different results: a mod-
erate frequency (4.5%, Virginia cohort) or a low fre-
quency similar to those of Belgium and Australia (1.6%,
Iowa cohort). A likely explanation for the higher fre-
quency observed in the Virginia cohort is that it contains
a higher proportion of individuals of Spanish descent
than does the Iowa cohort, but the contribution of other
factors cannot be excluded (for instance, differences in
the proportion of probands who were the offspring of
intermarriages among deaf people).
Before the screenings reported here, subjects with only
one mutant GJB2 allele accounted for 11.2%–51.5% of
those with (one or two) mutations in GJB2 in our co-
horts of cases. The lowest percentage was observed in
Italy (11.2%), a result that is consistent with the absence
of the deletion in that screening. In screenings performed
on large cohorts (150 subjects) in other countries, data
were, in general, rather homogeneous (22.1%–35.1%).
Differences between the two screenings in Spain are
probably due to regional bias in the Barcelona cohort
(40% of cases are from the same Spanish region, Can-
tabria). It is noteworthy that screenings not including
exon 1 and splice sites show percentages that are similar
to those that do include them, a result that suggests a
low frequency for mutations in these noncoding parts
of the gene.
As expected, the observed frequencies for the del(GJB6-
D13S1830) allele correlate with the percentage of cases
with only one mutant GJB2 allele that were elucidated
by the finding of the deletion (table 1). The highest figures
correspond to France, Spain, Israel, and the United King-
dom (31.6%–71.4%). Differences between the two Israeli
studies, both performed on Ashkenazi Jews, are likely to
be due to the small size of the cohorts that were analyzed.
On the other end, Australia, the United States, and Bel-
gium show much lower percentages of elucidated cases
(6.9%–15.9%). A slightly higher percentage was found
in an independent study performed in the United States
(Stevenson et al. 2003), with the deletion accounting for
20% of GJB2 deaf heterozygotes. After screening for the
deletion, cases that remain not elucidated fell to 16.0%–
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Table 2
Impact of Screening for del(GJB6-D13S1830) on the Elucidation of Cases with Only
One Mutant GJB2 Allele
COUNTRY/LABORATORY GJB2 TESTINGa
NO. OF MONOALLELIC SUBJECTS/
NO. OF MONOALLELIC 
NO. OF BIALLELIC SUBJECTSb
Before Screening
for the Deletion
After Screening
for the Deletion
Spain/Madrid Ex2-CR, Ex1, SpS 68/244 (27.9%) 39/244 (16.0%)c
Spain/Barcelona Ex2-CR, Ex1, SpS 35/68 (51.5%) 30/68 (44.1%)
Italy Ex2-CR 31/278 (11.2%) 31/278 (11.2%)
France Ex2-CR, Ex1, SpS 60/177 (33.9%) 37/177 (20.9%)
Belgium Ex2-CR 19/86 (22.1%) 17/86 (19.8%)
United Kingdom Ex2-CR 19/64 (29.7%) 13/64 (20.3%)
Israel/Tel Aviv Ex2-CR, Ex1, SpS 20/75 (26.7%) 13/75 (17.3%)
Israel/Jerusalem Ex2-CR, Ex1, SpS 7/44 (15.9%) 2/44 (4.5%)
United States/Virginia Ex2-CR, Ex1, SpS 88/251 (35.1%) 74/251 (29.5%)
United States/Iowa Ex2-CR, Ex1, SpS 95/305 (31.1%) 88/305 (28.9%)
Brazil Ex2-CR, Ex1, SpS 9/21 (42.9%) 7/21 (33.3%)
Australia Ex2-CR, Ex1, SpS 29/102 (28.4%) 27/102 (26.5%)
a Ex2-CR p exon 2 coding region; Ex1 p entire exon 1; SpS p splice sites.
b “Monoallelic” refers to subjects carrying only one mutant GJB2 allele; “biallelic”
refers to subjects carrying two mutant GJB2 alleles.
c After excluding cases not linked to DFNB1 according to haplotype analysis, results
were 28/244 (11.5%).
Table 3
Frequency of the del(GJB6-D13S1830) Allele
among the DFNB1 Alleles
Country/Laboratory
No. of del(GJB6-D13S1830)
Alleles/Total No. of DFNB1 allelesa
Spain/Madrid 31/408 (7.6%)
Spain/Barcelona 7/72 (9.7%)
Italy 0/494 (0%)
France 23/280 (8.2%)
Belgium 2/138 (1.4%)
United Kingdom 6/102 (5.9%)
Israel/Tel Aviv 9/126 (7.1%)
Israel/Jerusalem 5/84 (6.0%)
USA/Virginia 16/356 (4.5%)
USA/Iowa 7/434 (1.6%)
Brazil 2/28 (7.1%)
Australia 2/150 (1.3%)
a Only cases in which both DFNB1 alleles were identified
contribute to this total.
20.9% in France, Spain, and Israel (results from larger
cohorts) and are now closer to data from Italy (11.2%)
(table 2). Moreover, in the screening performed by the
Madrid team in Spain, genotyping and haplotype analysis
for genetic markers close to GJB2 allowed us to exclude
linkage to DFNB1 in 11 of 39 unelucidated cases, with
the percentage of unelucidated cases then decreasing to
11.5% (table 2). In contrast, these figures remain high in
all the other countries (19.8%–33.3% in Belgium, the
United Kingdom, Australia, the United States, and Brazil).
It is remarkable that Spanish subjects carrying a single
mutation in GJB2 but without linkage to DFNB1 (co-
incidental carriers) account for at least 4.5% (11 of 244;
data from the Madrid laboratory) of cases with GJB2
mutations. It must be taken into account that linkage to
DFNB1 cannot be tested in simplex (sporadic) cases, im-
peding the detection of additional coincidental carriers,
and so this figure undoubtedly is higher. However, even
if we assume a higher percentage of coincidental carriers,
it clearly emerges that other DFNB1 mutations remain
to be identified in most countries.
The frequency of the del(GJB6-D13S1830) mutation
in all populations is not high enough to result in a large
number of homozygous subjects. They represent !0.5%
of all cases of prelingual hearing impairment without
mutations in GJB2 (table 1; none were born from con-
sanguineous parents). It is noteworthy that four screen-
ings detected del(GJB6-D13S1830) heterozygotes with-
out accompanying DFNB1 mutation (table 1), which
are to be added to the cases lacking elucidation.
We investigated the evolutionary origins of the dele-
tion by studying haplotypes associated with this muta-
tion. Five microsatellite markers closely flanking the de-
letion breakpoints were selected for this study. Their
relative order and physical distances were as follows:
D13S1835–117 kb–(TG)n–42 kb–D13S141–68 kb–
(GAAA)n–4 kb–deletion proximal breakpoint–309 kb–
deletion distal breakpoint–233 kb–D13S1831. Note
that the deletion size, according to the latest sequencing
data, is 309 kb (National Center for Biotechnology In-
formation database, Homo sapiens genome view, build
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Table 4
Haplotypes Associated with the del(GJB6-D13S1830) Mutation
MARKERa
HETEROZYGOSITYb
(%)
ALLELE IN HAPLOTYPE
GENOTYPE
FOR CEPH
INDIVIDUAL
134702A1 A2 A3 A4 B1 B2 B3 B4 B5 B6 C1 D1 E1 E2 F1
D13S1835 78 134 134 134 136 132 132 134 136 136 138 136 134 138 165 138 134/136
(TG)n 65 204 204 204 204 208 208 208 208 208 208 210 204 208 208 208 206/208
D13S141 55 124 124 124 124 124 124 124 124 124 124 124 126 126 126 124 126/126
(GAAA)n 79 209 209 209 209 209 209 209 209 209 209 209 209 209 209 205 209/216
D13S1831 84 96 103 105 105 87 105 105 87 105 105 105 105 105 105 101 99/101
a Relative order and physical distances are as follows: D13S1835–117 kb–(TG)n–42 kb–D13S141–68 kb–(GAAA)n–4 kb–deletion proximal
breakpoint–309 kb–deletion distal breakpoint–233 kb–D13S1831.
b Calculated from 100 Spanish control chromosomes.
Table 5
Distribution of Haplotypes Associated with the Deletion in Different Populations
Haplotype N Distribution
Group A:
A1 1 Spain (Russian origin)
A2 1 Australia
A3 21 11 Spain (10 Madrid, 1 Barcelona) 8 Israel (6 Tel Aviv, 2 Jerusalem), 2 France
A4 1 Israel (Jerusalem)
Total 24
Group B:
B1 7 Spain (Madrid)
B2 2 Spain (Madrid)
B3 1 Spain (Madrid)
B4 1 Spain (Madrid)
B5 3 2 Spain (Madrid), 1 United Kingdom
B6 9 2 Spain (Madrid), 2 France, 1 United Kingdom, 1 Australia 1 United States (Virginia), 2 Brazil (Portuguese origin)
Total 23
Group C (C1) 1 France
Group D (D1) 1 United States (Virginia)
Group E:
E1 1 United Kingdom
E2 1 Spain (Madrid)
Total 2
Group F (F1) 1 United States (Virginia)
Total 52
33, contig NT_009799). Conditions for the PCR am-
plification of these markers have been reported elsewhere
(Hudson et al. 1992; Kibar et al. 1999; Lerer et al. 2001).
Cases suitable for haplotype analysis were genotyped for
these markers, but we report here only those cases in
which the haplotype associated with the deletion could
be determined unambiguously. These included 52 non-
related chromosomes: 28 from Spain (including 1 of
Russian origin), 9 from Israel, 5 from France, 3 from
the United Kingdom, 3 from the United States, 2 from
Brazil, and 2 from Australia (tables 4 and 5). Allele sizes
were determined by DNA sequencing of a control sam-
ple, which was shared by all the laboratories in this
multicenter study and was used as a standard in geno-
typing assays. To allow other laboratories to compare
their data with those reported in this work, we provide
allele sizes for individual 134702, available from CEPH
(Dib et al. 1996) (table 4).
In 51 of 52 chromosomes carrying the deletion, we
observed association with allele 209 from marker
(GAAA)n, which is at a distance of only 4 kb from the
deletion proximal breakpoint (frequency of this allele:
0.415 in Spain and 0.364 in Ashkenazi Jews). When con-
sidering a core haplotype constituted by markers (TG)n,
D13S141, and (GAAA)n, we could define six different
haplogroups, A–F (table 4). Finally, an expanded hap-
lotype with all the five markers revealed 15 variants as-
sociated with the deletion (table 4). When examining the
geographic distribution of haplotypes (table 5), it is re-
markable that all nine Israeli chromosomes belong to
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group A (eight A3 and one A4; these two haplotypes differ
only in D13S1835). Spanish haplotypes are mainly con-
centrated in groups A and B (11 A3, 15 B, and 1 E2),
and the two Brazilian chromosomes are B6. Most chro-
mosomes from other countries (France, the United King-
dom, and Australia) also belong to groups A and B. It is
noteworthy that two of three chromosomes from the
United States belong to groups D and F.
Our results show a clear founder effect for the
del(GJB6-D13S1830) mutation in Ashkenazi Jews in Is-
rael. Although the size of the sample should be increased
to reach firmer conclusions in most of the analyzed pop-
ulations, our data also suggest a common founder for
the deletion in some countries in western Europe, since
it is very scarce in Italy and has a low frequency in
Belgium, whereas it is quite frequent in Spain and
France, in Brazilian subjects of Portuguese origin, and—
although to a lesser extent—in the United Kingdom (in
all of these cases, the deletion is mainly associated with
haplogroups A and B). The fact that the Ashkenazi af-
fected subjects share a common haplotype along 464 kb
contrasts with the diversity of haplotypes found in pop-
ulations from western Europe, suggesting an older origin
for the deletion in these countries. The existence of hap-
logroup F also suggests that the deletion could have
other independent origins.
Inherited hearing impairment shows almost unparal-
leled genetic heterogeneity, not only in terms of numbers
of genes and mutations, but also in prevalence of specific
mutations among different populations. Therefore, data
from genetic epidemiological studies are essential for the
design of molecular diagnostic protocols well suited for
each population. Our study provides some conclusions
that should serve to improve the molecular diagnosis of
DFNB1 cases. Given the simplicity of the test for the
detection of the del(GJB6-D13S1830) mutation, it should
be performed for all subjects with prelingual hearing im-
pairment, at least in populations having higher frequen-
cies. Our work also highlights the importance of per-
forming haplotype analysis, when possible, in subjects
with only one mutant GJB2 allele, to identify carriers
whose hearing impairment might be due to mutations in
a different gene or to hypothetical epistatic interactions
between GJB2 mutations and other unlinked gene(s). This
step would also help to concentrate research on the elu-
cidation of cases consistent with linkage to DFNB1 by
investigating other parts of GJB2 (promoter, 3′ UTR) and
by searching for hypothetical point mutations in GJB6
or other DNA rearrangements in the DFNB1 locus.
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